A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
Phase 4
200
about 1.3 years
12+
35 sites in AL, AZ, CA +13
About this study
Researchers are testing how well lebrikizumab works for adults and adolescents with moderate atopic dermatitis, a condition causing itchy skin. The trial will last up to 38 weeks, including 6 months of treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Lebrikizumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
lebrikizumab
Primary: Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) (≥75% Reduction from Baseline in EASI), or a ≥4-point Reduction in Pruritus Numerical Rating Scale (NRS) from Baseline
Secondary: Change from Baseline in Body Surface Area (BSA) Involvement, Change from Baseline in Children's Dermatology Quality of Life (CDLQI), Change from Baseline in Dermatology Quality of Life (DLQI), Percentage Change from Baseline in Sleep-loss Scale, Percentage of Change from Baseline in Pruritus NRS Score, Percentage of Participants Achieving a ≥4-point Reduction from Baseline in Pruritus NRS, Percentage of Participants with a Skin Pain NRS of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction
Dermatology